Highlights include how cost-effective insulin reduces hospital visits; prevalence of restrictive lung disease in T2DM patients; and the wonders of self-monitoring for cost of care.
Surge in New GLP-1 Prescriptions Driven by Semaglutide's Popularity, Study Shows
Diabetes Dialogue: CATALYST Trial and Hypercortisolism in T2D, with John Buse, MD, PhD
FDA Issues Complete Response Letter for Once-Weekly Insulin Icodec
Diabetes Dialogue: ADA 2024 Diabetes Technology Recap
Tirzepatide Bests Semaglutide in Real-World Weight Loss Analysis
Endocrinology Month in Review: June 2024